Monica, John, David, and Marc join TWiV to discuss their work on identifying cryptic SARS-CoV-2 lineages in New York City wastewater, and understanding whether they were shed from humans or other animals.
TWiV reviews the results of a study in which 36 volunteers were infected with SARS-CoV-2, and what was learned about the kinetics of virus reproduction in the nose and throat, development of symptoms, and reliability of lateral flow antigen assays.
In COVID-19 clinical update #100, Daniel Griffin, from Accra, Ghana, reviews the challenges in evaluating Omicron severity, over 800 deaths in children, Pfizer vaccine EUA application for under 5 year olds, false positives from soft drinks, Novavax vaccine EUA application, childhood experiences and vaccine hesitancy, fourth vaccine dose in Israel, effects of antivirals and monoclonals against Omicron, and multiple factors associated with PASC.
Nels joins TWiV to discuss hypotheses for the origins of Omicron, including that it came from mice or arose during chronic infection of an immunocompromised patient.
TWiV reviews a seminal paper showing that chemically modified bases in RNAs suppress recognition by Toll-like receptors, a finding that that was essential for the development of COVID-19 mRNA vaccines.
In COVID-19 clinical update #99, Daniel Griffin discusses Omicron disease severity, neurologic manifestations in children, testing outcomes during multiple infections, boosters improve VE and VD, booster efficacy for ED and UC encounters, vaccines induce cross-protective T cell memory, and indications for monoclonal antibody therapy.
John Mascola joins TWiV to discuss the history and mission of the NIH Vaccine Research Center, how it prepared for devising pandemic vaccines, and development of the COVID-19 vaccines.
Jon Yewdell returns to TWiV to discuss how antibodies are made, vaccination against SARS-CoV-2, antigenic variation of the virus, booster shots, and more.
In COVID-19 clinical update #98, Daniel Griffin reviews COVID-19 in South Africa, recognition of Omicron by ancestral T cells, booster effectiveness against disease, infection and vaccination in pregnant women, early Remdesivir to prevent progression to severe disease, management of hospitalized adults, Tocilizumab in hospitalized patients, vaccination and long COVID, and the true toll of the pandemic.
Alessandro Sette returns to TWiV to discuss the observation that SARS-CoV-2 vaccination induces T cells that are able to cross-recognize variants Alpha to Omicron.